APPROACH Study

Mosaic Design APPROACH, a preventive vaccine study, seeks to address more than one clade by Jeannie Wraight Over the past thirty-plus years, strategies such as Treatment as...

Hurdles Cleared

Approved by the fda, telaprevir and boceprevir usher in a new era of treatment by Larry Buhl The first breakthrough treatments for liver disease to...

HCV Treatment Choices & Coverage Restrictions

Decisions, Decisions There are HCV treatment choices to make, but often few options by Larry Buhl If you’ve tested positive for the hepatitis C virus (HCV), there...

Eye on the Future

Towards an HIV Cure is an initiative of the International AIDS Society (IAS) formed to help direct and facilitate discussion, research and policy to...

amfAR Institute for HIV Cure Research: An Interview with Dr. Paul...

Hide & Seek Paul Volberding, MD, helps create synergy at the amfAR Institute for Cure Research by Jeannie Wraight The amfAR Institute for HIV Cure Research was...

HCV Institute

LifeGuide Mirror Image With a new institute for HCV, AAHIVM shows parallels between treating it and HIV by Larry Buhl More HIV providers are treating hepatitis C than...

Reforming HIV Laws in Texas

Lone Star Justice A new coalition in Texas aims to reform HIV criminalization & find a united voice for people living with HIV by Chip Alfred It’s...

Vpu Inhibitor Candidate

BIT225 is a new type of antiviral called a Vpu inhibitor, which researchers are investigating to treat both HIV and HIV/hepatitis C (HCV) co-infection....

Orphaned Vaccines

Sometimes viewing a complex issue in its most simplistic form can help us to understand where a problem lies. HIV is a virus that...

Smart Body Art

Do tattoos & piercings carry an increased HCV risk? by Larry Buhl In the U.S., an estimated thirty-six percent of people under thirty have tattoos, according...

LATEST POSTS

Meet Raymond Luczak, A&U’s New Fiction Editor

We are thrilled to welcome esteemed writer Raymond Luczak to our team as fiction editor. Raymond has been with the magazine from issue one—no...

Alan Ramírez: Advocate